Agree, boi, but I am talking about compliance in the real world. If 3-71 improves cognition to some degree and has fewer side effects, I believe, quite aside from efficacy on PANSS, it could generate better compliance than the BMY (Karuna) drug outside of inpatient populations.
Market Data 
Markets 
AI
